T-Cell Prolymphocytic Leukemia With t(X;14)(q28;q11.2): A Clinicopathologic Study of 15 Cases
American Journal of Clinical Pathology · 2023
DOI: 10.1093/ajcp/aqac166 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2023. Verfasst von Zhihong Hu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Leukemia, Prolymphocytic, T-Cell, Janus Kinase 3, STAT5 Transcription Factor. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Objectives
T-cell prolymphocytic leukemia (T-PLL) is a rare mature T-cell leukemia usually characterized by inv(14)(q11.2q32)/t(14;14)(q11.2;q32). In this study, we aimed to investigate the clinicopathologic features and molecular profile of T-PLL associated with t(X;14)(q28;q11.2).
Methods
The study group included 10 women and 5 men with a median age of 64 years. All 15 patients had a diagnosis of T-PLL with t(X;14)(q28;q11.2).
Results
All 15 patients had lymphocytosis at initial diagnosis. Morphologically, the leukemic cells had features of prolymphocytes in 11 patients, small cell variant in 3, and cerebriform variant in 1. All 15 patients had hypercellular bone marrow with an interstitial infiltrate in 12 (80%) cases. By flow cytometry, the leukemic cells were surface CD3+/CD5+/CD7+/CD26+/CD52+/TCR α/β+ in 15 (100%) cases, CD2+ in 14 (93%) cases, CD4+/CD8+ in 8 (53%) cases, CD4+/CD8– in 6 (40%) cases, and CD4–/CD8 + in 1 (7%) case. At the cytogenetic level, complex karyotypes with t(X;14)(q28;q11.2) were seen in all 15 patients assessed. Mutational analysis showed mutations of JAK3 in 5 of 6 and STAT5B p.N642H in 2 of 6 patients. Patients received variable treatments, including 12 with alemtuzumab. After a median follow-up of 17.2 months, 8 of 15 (53%) patients died.
Conclusions
T-PLL with t(X;14)(q28;q11.2) frequently shows a complex karyotype and mutations involving JAK/STAT pathway, and it is an aggressive disease with a poor outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Pathology, Yale University Medical Center, New Haven, CT, USA.
- Department of Laboratory Medicine & Pathology, Mayo Clinic, Minneapolis, MN, USA.
- Department of Pathology, Emory University, Atlanta, GA, USA.
- Department of Pathology, The University of Michigan Medical Center, Ann Arbor, MI, USAand Departments of.
Zitieren
APA
Hu, Z., Medeiros, L. J., Xu, M., Yuan, J., Peker, D., Shao, L., Tang, Z., Mai, B., Thakral, B., Rios, A., Hu, S., & Wang, W. (2023). T-Cell Prolymphocytic Leukemia With t(X;14)(q28;q11.2): A Clinicopathologic Study of 15 Cases. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqac166
Vancouver
Hu Z, Medeiros LJ, Xu M, Yuan J, Peker D, Shao L, et al. T-Cell Prolymphocytic Leukemia With t(X;14)(q28;q11.2): A Clinicopathologic Study of 15 Cases. American Journal of Clinical Pathology. 2023. doi:10.1093/ajcp/aqac166
BibTeX
@article{Hu2023,
author = {Hu, Zhihong and Medeiros, L Jeffrey and Xu, Mina and Yuan, Ji and Peker, Deniz and Shao, Lina and Tang, Zhenya and Mai, Brenda and Thakral, Beenu and Rios, Adan and Hu, Shimin and Wang, Wei},
title = {T-Cell Prolymphocytic Leukemia With t(X;14)(q28;q11.2): A Clinicopathologic Study of 15 Cases},
journal = {American Journal of Clinical Pathology},
year = {2023},
doi = {10.1093/ajcp/aqac166}
}
EUVIMED